Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Megna

Showing results (101-110 of 381) with videos related to

Pageof 39
Sort By:
Clinical, Cosmetic and Investigational Dermatology|March 24, 2025
Hidradenitis Suppurativa Cancer Risk: A Review of the LiteratureFabrizio Martora, Nello Tommasino, Teresa Battista, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 7, 2023
Reply to "Dalbavancin for the treatment of severe hidradenitis suppurativa"Fabrizio Martora, Angelo Ruggiero, Luca Potestio, et al.
International Journal of Dermatology|May 3, 2020
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?Matteo Megna, Claudio Marasca, Angelo Ruggiero, et al.
Dermatology (Basel, Switzerland)|December 9, 2020
Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico IIElisa Camela, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Journal of Cosmetic Dermatology|September 9, 2022
Pemphigus vulgaris and COVID-19 vaccination: Management and treatmentFabrizio Martora, Teresa Battista, Paola Nappa, et al.
The Journal of Dermatological Treatment|January 31, 2022
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life studyMatteo Megna, Luca Potestio, Angelo Ruggiero, et al.
The Journal of Dermatological Treatment|February 2, 2022
Letter to the editor submitted in response to 'Should the presence of psoriatic arthritis change how we manage psoriasis?'Matteo Megna, Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini, et al.
Psoriasis (Auckland, N.Z.)|May 11, 2023
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current LiteratureLuca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Dermatology (Basel, Switzerland)|July 14, 2020
Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin ScarsClaudio Marasca, Angelo Ruggiero, Dario Marasca, et al.
The Journal of Dermatological Treatment|July 25, 2020
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experienceMatteo Megna, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Pageof 39

Showing results (101-110 of 381) with videos related to

Sort By:
Pageof 39
Clinical, Cosmetic and Investigational Dermatology|March 24, 2025
Hidradenitis Suppurativa Cancer Risk: A Review of the LiteratureFabrizio Martora, Nello Tommasino, Teresa Battista, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 7, 2023
Reply to "Dalbavancin for the treatment of severe hidradenitis suppurativa"Fabrizio Martora, Angelo Ruggiero, Luca Potestio, et al.
International Journal of Dermatology|May 3, 2020
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?Matteo Megna, Claudio Marasca, Angelo Ruggiero, et al.
Dermatology (Basel, Switzerland)|December 9, 2020
Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico IIElisa Camela, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Journal of Cosmetic Dermatology|September 9, 2022
Pemphigus vulgaris and COVID-19 vaccination: Management and treatmentFabrizio Martora, Teresa Battista, Paola Nappa, et al.
The Journal of Dermatological Treatment|January 31, 2022
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life studyMatteo Megna, Luca Potestio, Angelo Ruggiero, et al.
The Journal of Dermatological Treatment|February 2, 2022
Letter to the editor submitted in response to 'Should the presence of psoriatic arthritis change how we manage psoriasis?'Matteo Megna, Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini, et al.
Psoriasis (Auckland, N.Z.)|May 11, 2023
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current LiteratureLuca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Dermatology (Basel, Switzerland)|July 14, 2020
Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin ScarsClaudio Marasca, Angelo Ruggiero, Dario Marasca, et al.
The Journal of Dermatological Treatment|July 25, 2020
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experienceMatteo Megna, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Pageof 39